Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Trial of Olutasidenib in Relapsed/Refractory IDH1-Mutated AML
jRCT2051260041Phase 2Recruiting
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olutasidenib in acute myeloid leukemia (AML), sponsored by Kissei Pharmaceutical Co., Ltd. Primary endpoint: Incidence of adverse events and adverse drug reactions. Started Feb 2026; status: recruiting.
02
Drugs
olutasidenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on jRCT2051260041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051260041.